实用肿瘤学杂志 ›› 2020, Vol. 34 ›› Issue (5): 412-417.doi: 10.11904/j.issn.1002-3070.2020.05.005

• 基础研究 • 上一篇    下一篇

99mTc-HYNIC-MPG在体非小细胞肺癌分子分型研究

闫䶮1, 侯利芳2, 李任飞1, 闫鹏1, 王月东3, 郑玉婷1   

  1. 1.哈尔滨医科大学附属第四医院介入科(哈尔滨 150001);
    2.哈尔滨医科大学附属第一医院超声科;
    3.山东省立医院介入科
  • 收稿日期:2020-04-06 出版日期:2020-10-28 发布日期:2020-11-02
  • 通讯作者: 郑玉婷,E-mail:1098512958@qq.com
  • 作者简介:闫䶮,男,(1985-),博士,副主任医师,从事分子影像及介入放射学的研究。
  • 基金资助:
    黑龙江省2018博士后资助课题(编号:LBH-Z18229);黑龙江省卫生计生委科研课题(编号:2018410)

Imaging with 99mTc-HYNIC-MPG molecular typing of non-small cell lung cancer in vivo

YAN Yan1, HOU Lifang2, LI Renfei1, YAN Peng1, WANG Yuedong3, ZHENG Yuting1   

  1. 1. Department of Interventional Radiology,The Fourth Affiliated Hospital of Harbin Medical University,Harbin 150001,China;
    2. Department of Ultrasound,The First Affiliated Hospital of Harbin Medical University;
    3. Department of Interventional Radiology of Shandong Western Provincial Hospital
  • Received:2020-04-06 Online:2020-10-28 Published:2020-11-02

摘要: 目的 合成靶向突变表皮生长因子受体(EGFR)的特异性探针99mTc-HYNIC-MPG,并用于实时、在体判定非小细胞肺癌EGFR突变情况。方法 一步法合成99mTc-HYNIC-MPG,分为人非小细胞肺癌PC9(实验组,19外显子缺失)、人非小细胞肺癌细胞系H358(对照组,EGFR野生型)、人非小细胞肺癌H520(对照组,EGFR阴性)和人非小细胞肺癌H1975(对照组,T790M/L858R二次突变)。四种细胞系行99mTc-HYNIC-MPG探针的细胞摄取、释放及阻断实验。四种不同的细胞系构建荷瘤裸鼠动物模型,于1、2、4和6h行单光子发射计算机断层显像(SPECT)成像和生物体内分布。使用PD153035(100mg/kg)验证能否阻断PC9细胞系荷瘤鼠模型对探针的摄取。结果 99mTc-HYNIC-MPG探针的标记率高达98%。PC9细胞系对99mTc-HYNIC-MPG摄取率最高,可达到(23.79±0.63)%。PD153035(100μmol/L)能够阻断摄取,摄取率降低为(1.90±0.06)%。生物体内分布实验表明PC9细胞系于2h达到高峰(7.20±0.27)%ID/g,而H358、H520和H1975三种细胞系肿瘤摄取明显低。SPECT成像结果也表明PC9细胞系荷瘤鼠模型的肿瘤对99mTc-HYNIC-MPG的摄取高。结论 99mTc-HYNIC-MPG探针特异性、靶向性强,能够与19外显子缺失的EGFR突变特异性结合,有望真正实现肺癌在体分子分型。

关键词: 99mTc-HYNIC-MPG, 突变EGFR, 酪氨酸激酶抑制剂, 非小细胞肺癌, SPECT, 分子影像

Abstract: Objective The objectives of this study were to synthesis a specific probe 99mTc-HYNIC-MPG targeting mutant epidermal growth factor receptor(EGFR)and use it to determine the EGFR mutation status of non-small lung cell cancer(NSCLS)in real-time and in vivo.Methods One-step synthesis of 99mTc-HYNIC-MPG was divided into human non-small cell lung cancer PC9(experimental group,exon 19 deletion),H358(control group,EGFR wild type),H520(control group,EGFR negative),and H1975(T790m/L858R secondary mutation).The four cell lines were subjected to 99mTc-HYNIC-MPG probe for cell uptake,release and blocking experiments.Four different cell lines were used to construct animal models of tumor-bearing nude mice,and single-photon emission computed tomography(SPECT)imaging and biological distribution were performed at 1,2,4,and 6h.PD153035(100mg/kg)was used to verify whether it could block the uptake of the probe by PC9 cells for a tumor-bearing mouse model.Results The labeling rate of 99mTc-HYNIC-MPG probe was as high as 98%.PC9 cells had the highest uptake rate of 99mTc-HYNIC-MPG,which could reach(23.79±0.63)%.PD153035(100μmol/L)could block uptake and the uptake rate was reduced to(1.90±0.06)%.The distribution experiment in vivo showed that PC9 cells reached a peak(7.20±0.27)%ID/g at 2h,while the tumor uptake of H358,H520 and H1975 cell lines was significantly lower.The SPECT imaging results also showed that the tumor of the PC9 cells tumor-bearing mouse model had a high uptake of 99mTc-HYNIC-MPG.Conclusion The 99mTc-HYNIC-MPG probe is specific and targeted,can specificity bind to the EGFR mutation with deletion of exon 19,and is expected to truly achieve in vivo molecular typing of lung cancer.

Key words: 99mTc-HYNIC-MPG, Mutated EGFR, Tyrosine kinase inhibitor, Non-small cell lung cancer, SPECT, Molecular imaging

中图分类号: